Companies › Alto Neuroscience
4 active drug programs in 4 registered trials: 4 Phase 2; Psychiatry; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ALTO-300 | – | Phase 2 | Major Depressive Disorder | Dec 2026 |
| ALTO-100 | – | Phase 2 | Bipolar Disorder I or II With a Major Depressive Episode | Sep 2027 |
| ALTO-207 | – | Phase 2 | Treatment-resistant Depression (TRD) | Nov 2027 |
| ALTO-101 | – | Phase 2 | Schizophrenia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06502964 | ALTO-101 | Phase 2 | Schizophrenia | Psychiatry | Feb 2026 |
| NCT05922878 | ALTO-300 | Phase 2 | Major Depressive Disorder | Psychiatry | Dec 2026 |
| NCT06656416 | ALTO-100 | Phase 2 | Bipolar Disorder I or II With a Major Depressive Episode | Psychiatry | Sep 2027 |
| NCT07553637 | ALTO-207 | Phase 2 | Treatment-resistant Depression (TRD) | Psychiatry | Nov 2027 |
Cash of $244m on 2026-06-30; operating cash outflow about $95m a year; runway about 31 months at that burn, to Jan 2029; 3 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Seaport Therapeutics LB Pharmaceuticals Definium Therapeutics US Anavex Life Sciences Draig Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.